Charles River Laboratories (CRL) Tops Q2 EPS by 32c, Lifts Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Charles River Laboratories Announces Second-Quarter 2020 Results
August 5, 2020 7:00 AM EDTSecond-Quarter Revenue of $682.6 Million
Second-Quarter GAAP Earnings per Share of $1.34 and Non-GAAP Earnings per Share of $1.58
Increases 2020 Guidance
Announces Proposed Acquisition of Cellero in the High-Growth Cell Therapy Market
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2020. For the quarter, revenue was $682.6 million, an increase of 3.8% from $657.6 million in the second quarter of 2019.
Acquisitions contributed 3.2% to consolidated second-quarter revenue growth. The impact of... More
